Centessa Pharmaceuticals ADR Aktie Logo
US1523091007
A3CQ72
CNTA

Centessa Pharmaceuticals ADR Aktie

Loading quotes...

Forecast

The analysts' average price target is €36.46 (+2.79%). The median is €36.46 (+2.79%).

Buy
  8
Hold
  6
Sell
  0

Discussions in the community

There is no discussion about this asset yet.

Start discussion

  • Centessa announces CEO change; shares fall after strategic realignment

    Centessa reports that Mario Alberto Accardi will replace Saurabh Saha as CEO on January 1, 2026, and join the board; Saha is stepping down and will remain as an adviser. The stock subsequently fell about 4%. The company is refocusing its strategy on the orexin/OX2R portfolio: lead candidate ORX750 is expected to enter an approval-relevant program for narcolepsy and idiopathic hypersomnia in the first quarter of 2026, and other OX2R candidates such as ORX142 and ORX489 are expected to hit key milestones in 2026. » More on de.investing.com


  • Centessa Pharmaceuticals hits 52-week high at $25.44

    The ADRs of Centessa Pharmaceuticals rose to a 52-week high of $25.44 after the stock gained 32.59% over the past year and 71.41% in six months; the current price is about 166% above the annual low of $9.60. Analyst price targets range from $27 to $49, while InvestingPro flags a possible overvaluation versus fair value. Centessa announced a public offering of 11.6 million ADS at $21.50 (gross proceeds ~ $250 million, fully underwritten) and received a buy from Truist with a $30.00 target following preliminary phase-2a data on ORX750. » More on de.investing.com


  • Centessa announces public offering of ADS, shares fall in after-hours

    Centessa's share fell about 2.5% in after-hours trading after the company announced a guaranteed public placement of American Depositary Shares (each representing one common share). All offered ADS will be sold by Centessa, and the underwriting banks have a 30-day option to purchase up to 15% of the shares. Jefferies, Leerink Partners, Evercore ISI and Guggenheim Securities are joint bookrunners; the offering is subject to market and other conditions and may lead to dilution for existing shareholders. » More on de.investing.com


  • Centessa Pharmaceuticals sets ADS offering price at $21.50

    Centessa Pharmaceuticals sets the price for a public, syndicated offering of 11,627,907 American Depositary Shares (ADS) at $21.50 per ADS and expects gross proceeds of about $250 million before expenses. The transaction, in which all of Centessa’s ADSs will be sold, is expected to close around November 14, 2025, and includes a 30-day overallotment option for up to 1,744,186 ADS. Joint book-running managers are Jefferies, Leerink Partners, Evercore ISI and Guggenheim Securities; the ADSs are being offered on the basis of a Form S-3 filed in September 2024. » More on de.investing.com


  • Centessa Pharmaceuticals hits 52-week high at $25.35

    Centessa Pharmaceuticals ADRs marked a new 52-week high at $25.35 and are up about 56.7% year to date. Market capitalization is roughly $3.34 billion; analyst price targets range from $27 to $40, with Stephens, Oppenheimer and Truist recently issuing buy recommendations or positive ratings. Key upcoming events include the quarterly report on November 17 and expected Phase‑2a data for ORX750 before year‑end. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics
In 2026, Centessa Pharmaceuticals ADR Aktie has already paid €33.47 in dividends. The last payout was in June.

Financials

In the last quarter, Centessa Pharmaceuticals ADR Aktie had revenue of €0 and net profit of -€68.46M
(EUR) March 2026
YoY
Revenue 0 -
Gross profit -206.13K -
Net profit -68.46M -
EBITDA -65.16M -

Fundamentals

Metric Value
Market capitalization
€5.71B
Number of shares
154.73M
52-week high/low
€36.97 - €11.65
Dividend yield
94.36%
Dividends TTM
€33.47
Beta
1.12
P/E ratio
-22.75
PEG ratio
3.15
P/B ratio
12.76
P/S ratio
0.00

Company profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; and SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B. The company also has emerging pipeline products under clinical proof of concept stage comprising LB101, a PD-L1xCD47 LockBody, as well as LB201, a PD-L1xCD3 LockBody, which are designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; ZF874, a small molecule pharmacological chaperone folding corrector of the Z variant of alpha-1-antitrypsin in Phase I clinical development for the treatment of alpha-1-antitrypsin deficiency; MGX292, a recombinant modified BMP9 replacement protein designed to overcome the deficiency in BMP9 signaling in Pulmonary Arterial Hypertension; and OX2R Agonists that are oral and intranasal selective orexin receptor 2 agonists designed to leverage structural insights and to directly target the underlying pathophysiology of orexin neuron loss in Narcolepsy Type 1. In addition, the company has exploratory pipeline products under clinical proof of concept stage containing CBS001, an anti-LIGHT antibody, which preferentially binds the inflammatory membrane form of LIGHT in inflammatory/fibrotic diseases; and CBS004, a humanized mAb specific to BDCA2, expressed exclusively on plasmacytoid dendritic cells in systemic sclerosis, systemic lupus erythematosus, and other autoimmune diseases. Centessa Pharmaceuticals plc was incorporated in 2020 and is based in Altrincham, the United Kingdom.

Name
Centessa Pharmaceuticals ADR Aktie
CEO
Mario Alberto Accardi
Headquarters Altrincham,
United Kingdom
Website
Sector
Materials
Industry
Chemicals
IPO
05/28/2021
Employees 129

Ticker symbols

Exchange Symbol
NASDAQ
CNTA
Frankfurt
260.F
Düsseldorf
260.DU
München
260.MU
London
0ACX.L
🍪

Parqet  uses cookies. Learn more